Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

8.860 +0.090 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 Next >
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Outlook For Aurinia Pharmaceuticals
Via Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0.19), sales $45.1 million. AUR200 development halted. Strategic review concludes. $150 million share buyback initiated. 
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To... 
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week. 
Via Benzinga
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation. 
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Slumping Today
The biotech's premium valuation doesn't seem to be sitting well with investors. 
Via The Motley Fool
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Aurinia Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
Investors appear to be cheering another patent win by the company. 
Via The Motley Fool
Aurinia Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Preview: Aurinia Pharmaceuticals's Earnings
Via Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say. 
Via Investor's Business Daily
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or  
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
Via Benzinga
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run. 
Via The Motley Fool
What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA 
Via Benzinga
What's Going On With Aurinia Pharmaceuticals Stock Today?
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales fig 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.